MTOR and neoplasm: A prospective analysis of tumor DNA from 127 patients, as reported by Harding et al., showed that alterations in the PI3K-mTOR pathway were associated with lower disease control rates, shorter mPFS (HR, 3.8; 95% CI, 2.0 – 7.5; p <0.0001), and shorter mOS (HR, 10.4; 95% CI, 1.21 – 5.31; p = 0.01).